Role of lymphadenectomy in intermediate-risk endometrial cancer: a matched-pair study

J Gynecol Oncol. 2018 Jan;29(1):e1. doi: 10.3802/jgo.2018.29.e1.

Abstract

Objective: To assess the impact of lymph node dissection (LND) on morbidity, survival, and cost for intermediate-risk endometrial cancers (IREC).

Methods: A multicenter retrospective cohort of 720 women with IREC (endometrioid histology with myometrial invasion <50% and grade 3; or myometrial invasion ≥50% and grades 1-2; or cervical involvement and grades 1-2) was carried out. All patients underwent hysterectomy and bilateral salpingo-oophorectomy. A matched pair analysis identified 178 pairs (178 with LND and 178 without it) equal in age, body mass index, co-morbidities, American Society of Anesthesiologist score, myometrial invasion, and surgical approach. Demographic data, pathology results, perioperative morbidity, and survival were abstracted from medical records. Disease-free survival (DFS) and overall survival (OS) was analyzed using Kaplan-Meier curves and multivariate Cox regression analysis. Cost analysis was carried out between both groups.

Results: Both study groups were homogeneous in demographic data and pathologic results. The mean follow-up in patients free of disease was 61.7 months (range, 12.0-275.5). DFS (hazard ratio [HR]=1.34; 95% confidence interval [CI]=0.79-2.28) and OS (HR=0.72; 95% CI=0.42-1.23) were similar in both groups, independently of nodes count. In LND group, positive nodes were found in 10 cases (5.6%). Operating time and late postoperative complications were higher in LND group (p<0.05). Infection rate was significantly higher in no-LND group (p=0.035). There were no statistical differences between both groups regarding operative morbidity and hospital stay. The global cost was similar for both groups.

Conclusion: Systematic LND in IREC has no benefit on survival, although it does not show an increase in perioperative morbidity or global cost.

Keywords: Costs and Cost Analysis; Endometrial Neoplasms; Lymph Node Excision; Morbidity; Risk Factors; Survival.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cost-Benefit Analysis
  • Endometrial Neoplasms / economics
  • Endometrial Neoplasms / epidemiology
  • Endometrial Neoplasms / pathology*
  • Endometrial Neoplasms / surgery*
  • Female
  • Humans
  • Lymph Node Excision* / adverse effects
  • Lymph Node Excision* / economics
  • Lymph Node Excision* / statistics & numerical data
  • Lymphatic Metastasis
  • Matched-Pair Analysis
  • Middle Aged
  • Morbidity
  • Neoplasm Staging
  • Postoperative Complications / economics
  • Postoperative Complications / epidemiology
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Survival Analysis
  • Treatment Outcome
  • Uterine Neoplasms / economics
  • Uterine Neoplasms / epidemiology
  • Uterine Neoplasms / pathology*
  • Uterine Neoplasms / surgery*